| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | 10.4B | 171.16 | 19.79 | 6.12% | -8.86% | -9.31% | 12.96% | 1.51 |
| ACADACADIA Pharmaceuticals Inc. | 4.49B | 26.53 | 19.51 | 31.85% | 24.94% | 28.47% | 3.5% | 0.07 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.82B | 22.96 | 17.53 | 23.49% | 37.63% | 23.64% | 8.48% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.1B | 36.41 | 14.51 | 22.8% | 22.48% | 22.23% | 10.43% | 0.28 |
| ALKSAlkermes plc | 5.15B | 31.22 | 14.39 | -6.36% | 22.27% | 19.55% | 7.87% | 0.05 |
| PRTCPureTech Health plc | 463.31M | 19.17 | 9.59 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 540.89M | 21.38 | -1.20 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 361.97M | 2.13 | -1.39 | -178.79% | 0.01 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 210K | 0 | 0 | 0 |
| Revenue Growth % | - | -1% | - | - |
| Cost of Goods Sold | 145K | 342K | 0 | 502K |
| COGS % of Revenue | 0.69% | - | - | - |
| Gross Profit | 65K | -342K | 0 | -502K |
| Gross Margin % | 0.31% | - | - | - |
| Gross Profit Growth % | - | -6.26% | 1% | - |
| Operating Expenses | 12.12M | 28.85M | 37.81M | 68.11M |
| OpEx % of Revenue | 57.72% | - | - | - |
| Selling, General & Admin | 3.75M | 5.16M | 7.52M | 21.61M |
| SG&A % of Revenue | 17.86% | - | - | - |
| Research & Development | 8.37M | 23.69M | 30.29M | 47M |
| R&D % of Revenue | 39.86% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -502K |
| Operating Income | -12.06M | -29.19M | -37.81M | -68.61M |
| Operating Margin % | -57.41% | - | - | - |
| Operating Income Growth % | - | -1.42% | -0.3% | -0.81% |
| EBITDA | -11.91M | -28.85M | -37.44M | -74.41M |
| EBITDA Margin % | -56.72% | - | - | - |
| EBITDA Growth % | - | -1.42% | -0.3% | -0.99% |
| D&A (Non-Cash Add-back) | 145K | 342K | 373K | -5.8M |
| EBIT | -9.19M | -27.71M | -34.94M | -62.81M |
| Net Interest Income | 2K | 114K | 979K | 10.23M |
| Interest Income | 2K | 114K | 2.35M | 8.85M |
| Interest Expense | 0 | 0 | 1.37M | -1.38M |
| Other Income/Expense | 2.87M | 1.48M | 1.5M | 7.18M |
| Pretax Income | -9.19M | -27.71M | -36.3M | -61.43M |
| Pretax Margin % | -43.75% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% |
| Net Income | -9.19M | -27.71M | -36.3M | -61.43M |
| Net Margin % | -43.75% | - | - | - |
| Net Income Growth % | - | -2.02% | -0.31% | -0.69% |
| Net Income (Continuing) | -9.19M | -27.71M | -36.3M | -61.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.36 | -1.08 | -1.35 | -2.50 |
| EPS Growth % | - | -2% | -0.25% | -0.85% |
| EPS (Basic) | -0.36 | -1.08 | -1.35 | -2.50 |
| Diluted Shares Outstanding | 25.57M | 25.57M | 26.88M | 24.6M |
| Basic Shares Outstanding | 25.57M | 25.57M | 26.88M | 24.6M |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 27.68M | 49.22M | 85.39M | 169.34M |
| Cash & Short-Term Investments | 25.7M | 48.34M | 82.55M | 168.23M |
| Cash Only | 25.7M | 48.34M | 82.55M | 168.23M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.74M | 546K | 8K | 0 |
| Days Sales Outstanding | 3.03K | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 0 | 0 | 2.31M | 30K |
| Total Non-Current Assets | 1.11M | 1.63M | 1.24M | 8.21M |
| Property, Plant & Equipment | 1.06M | 1.58M | 1.11M | 7.7M |
| Fixed Asset Turnover | 0.20x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 500K |
| Other Non-Current Assets | 50K | 55K | 131K | 4K |
| Total Assets | 28.79M | 50.85M | 86.63M | 177.54M |
| Asset Turnover | 0.01x | - | - | - |
| Asset Growth % | - | 0.77% | 0.7% | 1.05% |
| Total Current Liabilities | 1.81M | 5.56M | 5.61M | 10.01M |
| Accounts Payable | 600K | 1.61M | 1.07M | 1.58M |
| Days Payables Outstanding | 1.51K | 1.71K | - | 1.15K |
| Short-Term Debt | 0 | 283K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.19M | 3.54M | 0 | 0 |
| Current Ratio | 15.30x | 8.85x | 15.22x | 16.92x |
| Quick Ratio | 15.30x | 8.85x | 15.22x | 16.92x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 39.46M | 83.7M | 152.69M | 16.07M |
| Long-Term Debt | 38.16M | 81.7M | 9.86M | 11.56M |
| Capital Lease Obligations | 0 | 123K | 0 | 4.52M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.3M | 1.88M | 142.83M | 0 |
| Total Liabilities | 41.27M | 89.26M | 158.3M | 26.08M |
| Total Debt | 38.16M | 82.11M | 9.99M | 16.94M |
| Net Debt | 12.46M | 33.76M | -72.56M | -151.28M |
| Debt / Equity | - | - | - | 0.11x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | - | - | -27.60x | - |
| Total Equity | -12.48M | -38.41M | -71.67M | 151.46M |
| Equity Growth % | - | -2.08% | -0.87% | 3.11% |
| Book Value per Share | -0.49 | -1.50 | -2.67 | 6.16 |
| Total Shareholders' Equity | -12.48M | -38.41M | -71.67M | 151.46M |
| Common Stock | 1K | 1K | 0 | 3K |
| Retained Earnings | -12.95M | -40.66M | -76.97M | -138.4M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | -22K | -46K | -79K | -101K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | -9.26M | -20.39M | -33.45M | -47.42M |
| Operating CF Margin % | -44.1% | - | - | - |
| Operating CF Growth % | - | -1.2% | -0.64% | -0.42% |
| Net Income | -9.19M | -27.71M | -36.3M | -61.43M |
| Depreciation & Amortization | 145K | 342K | 373K | 502K |
| Stock-Based Compensation | 227K | 1.76M | 2.89M | 7.63M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 125K | 632K | 291K | 1.81M |
| Working Capital Changes | -572K | 4.58M | -698K | 4.06M |
| Change in Receivables | -1.28M | 1.16M | 325K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 458K | 1.01M | -632K | 516K |
| Cash from Investing | -680K | -732K | -470K | -2.08M |
| Capital Expenditures | -680K | -732K | -470K | -2.08M |
| CapEx % of Revenue | 3.24% | - | - | - |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 31.69M | 43.79M | 68.13M | 135.69M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | -205K | -341K | -1.87M | -3.14M |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | -9.94M | -21.13M | -33.92M | -49.5M |
| FCF Margin % | -47.34% | - | - | - |
| FCF Growth % | - | -1.12% | -0.61% | -0.46% |
| FCF per Share | -0.39 | -0.83 | -1.26 | -2.01 |
| FCF Conversion (FCF/Net Income) | 1.01x | 0.74x | 0.92x | 0.77x |
| Interest Paid | 0 | 0 | 912K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -153.99% |
| Gross Margin | 30.95% | - | - | - |
| Net Margin | -4374.76% | - | - | - |
| Debt / Equity | - | - | - | 0.11x |
| Interest Coverage | - | - | -27.60x | - |
| FCF Conversion | 1.01x | 0.74x | 0.92x | 0.77x |
| Revenue Growth | - | -100% | - | - |
Alto Neuroscience, Inc. (ANRO) grew revenue by 0.0% over the past year. Growth has been modest.
Alto Neuroscience, Inc. (ANRO) reported a net loss of $62.3M for fiscal year 2024.
Alto Neuroscience, Inc. (ANRO) has a return on equity (ROE) of -154.0%. Negative ROE indicates the company is unprofitable.
Alto Neuroscience, Inc. (ANRO) had negative free cash flow of $53.8M in fiscal year 2024, likely due to heavy capital investments.